Sugi Predict

Sugi Predict / Compounds / SCHEMBL1330352

SCHEMBL1330352

SCHEMBL1330352

CC(C)(C)OC(=O)N1CCC[C@@H](C(=O)O)N1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.50
▸ CTSK P43235 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ LMNA P02545 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6509973 1.00 HSD17B10 (0.50) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL9386894 1.00 HSD17B10 (0.50) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL29985720 0.92 HSD17B10 (0.49) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL15447605 0.85 CTSK (0.43) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL19479525 0.85 CTSK (0.43) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL12643647 0.85 L3MBTL1 (0.44) HSD17B10CTSKSMN1; SMN2LMNAMEN1
SCHEMBL7518566 0.83 HSD17B10 (0.49) HSD17B10SMN1; SMN2LMNAHPGDMEN1
SCHEMBL4845470 0.81 FKBP1A (0.45) HSD17B10CTSKSMN1; SMN2LMNAHPGD
SCHEMBL15443470 0.79 CTSK (0.42) HSD17B10CTSKSMN1; SMN2HPGDMEN1
SCHEMBL18562067 0.79 CTSK (0.42) HSD17B10CTSKSMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695233-A2 SYNTHESIS OF RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
WO-2025201453-A1 MACROCYCLIC COMPOUNDS AS RAS INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 — — WO disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CYPRALIS LIMITED (GB) 2025-07-31 — — US disclosed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 — — US disclosed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 — — US disclosed
US-20110281845-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-11-17 — — US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 — — US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 — — US disclosed
US-7989441-B2 Organic compounds NOVARTIS AG (CH) 2011-08-02 — — US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 — — US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 — — US disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 — — US disclosed
WO-1994011353-A1 PROCESS FOR THE PREPARATION OF (3R)- AND (3S)-PIPERAZIC ACID DERIVATIVES UNIVERSITY COLLEGE LONDON (GB) 1994-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069294-A1 Organic Compounds XIAP, BAX, MCL1 HSD17B10 2699/4885CTSK 3081/4885SMN1; SMN2 1005/4885
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885
US-20110281845-A1 ORGANIC COMPOUNDS XIAP, BAX, MCL1 HSD17B10 2700/4885CTSK 3080/4885SMN1; SMN2 1006/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CASP3, TNNC1, BAD HSD17B10 2628/4885CTSK 234/4885SMN1; SMN2 79/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS HSD17B10 4458/4885CTSK 1458/4885SMN1; SMN2 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.